BCAB241220P5000
- 0.00
- 0.000.00%
BioAtla Newsroom
Express News | BioAtla Shares Are Trading Lower. The Stock May Be Reacting to the Scion Asset Management 13F Filing Disclosing an Exit From Their Position in the Company
Express News | Scion Asset Management 13F Shows Exited Position In Hudson Pacific Properties, Previously Holding 1,144,435 Shares; Exited Position In BioAtla, Previously Holding 633,959 Shares
BioAtla Analyst Ratings
H.C. Wainwright Downgrades BioAtla(BCAB.US) to Hold Rating
BioAtla Downgraded to Neutral From Buy at H.C. Wainwright
JMP Securities Maintains BioAtla(BCAB.US) With Buy Rating, Maintains Target Price $5
BioAtla: Strong Financials and Promising Clinical Progress Drive Buy Rating
BioAtla, Inc. (BCAB) Q3 2024 Earnings Call Transcript Summary
BioAtla Reports Q3 2024 Financial Results and Clinical Advances
BioAtla | 10-Q: Q3 2024 Earnings Report
BioAtla Reports Q3 EPS (22c), Consensus (36c)
BioAtla | 8-K: BIOATLA REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PROGRESS
Express News | Bioatla Q3 Operating Expenses USD 22.27 Million
Press Release: BioAtla Reports Third Quarter 2024 Financial Results and Highlights Recent Progress
Earnings Preview: BioAtla to Report Financial Results Post-market on November 07
BioAtla, Inc. (NASDAQ:BCAB) Has Caught the Attention of Institutional Investors Who Hold a Sizeable 39% Stake
BioAtla Inc (BCAB) Q2 2024 Earnings Call Highlights: Strategic Progress Amid Financial Challenges
'Big Short' Investor Michael Burry's China Bet Pays Off As Top Picks Surge Nearly 60% In 2 Months
12 Health Care Stocks Moving In Wednesday's Intraday Session
Express News | Bioatla Announces Upcoming Oral Presentation at the Society for Melanoma Research 21St International Congress